Hepatitis C Management in Special Populations

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 8/17/18 (What's New)

Summary

  • Data indicate that HCV therapy with DAAs is generally safe and effective in patients with renal dysfunction, and DAAs do not require dose reduction in patients with mild to moderate renal impairment[AASLD-IDSA HCV]
  • The decision to treat is based on liver disease stage, likelihood of sustained virologic response, and comorbid conditions
  • AASLD/IDSA recommendations for HCV treatment in patients with severe renal impairment or ESRD summarized in Table 2[AASLD-IDSA HCV]

Action required